BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 30606633)

  • 21. Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis.
    Li X; Li C; Wang R; Ren J; Yang J; Zhang Y
    PLoS One; 2015; 10(12):e0144247. PubMed ID: 26629904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging.
    Moon JY; Kim SH; Choi SY; Hwang JA; Lee JE; Lee J
    Jpn J Radiol; 2018 Aug; 36(8):489-499. PubMed ID: 29876721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-Hypervascular Hypointense Nodules at Gadoxetic Acid MRI: Hepatocellular Carcinoma Risk Assessment with Emphasis on the Role of Diffusion-Weighted Imaging.
    Briani C; Di Pietropaolo M; Marignani M; Carbonetti F; Begini P; David V; Iannicelli E
    J Gastrointest Cancer; 2018 Sep; 49(3):302-310. PubMed ID: 28547117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.
    Han SB; Kim YK; Min JH; Ha SY; Jeong WK; Lee WJ
    Acta Radiol; 2018 Apr; 59(4):393-401. PubMed ID: 28760004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coefficient of variation on Gd-EOB MR imaging: Correlation with the presence of early-stage hepatocellular carcinoma in patients with chronic hepatitis B.
    Lee JH; Kim YR; Lee GM; Ryu JH; Cho EY; Lee YH; Yoon KH
    Eur J Radiol; 2018 May; 102():95-101. PubMed ID: 29685552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.
    Kang HJ; Lee JM; Yoon JH; Han JK
    Korean J Radiol; 2021 Mar; 22(3):354-365. PubMed ID: 33236540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of diffusion-weighted imaging and gadoxetic acid-enhanced MR images in the evaluation of hepatocellular carcinoma and hypovascular hepatocellular nodules.
    Di Pietropaolo M; Briani C; Federici GF; Marignani M; Begini P; Delle Fave G; Iannicelli E
    Clin Imaging; 2015; 39(3):468-75. PubMed ID: 25748089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of high-stage liver fibrosis using ADC value on diffusion-weighted imaging and quantitative enhancement ratio at the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI at 1.5 T.
    Harada TL; Saito K; Araki Y; Matsubayashi J; Nagao T; Sugimoto K; Tokuuye K
    Acta Radiol; 2018 May; 59(5):509-516. PubMed ID: 28853292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visibility of focal liver lesions: Comparison between kupffer phase of CEUS with sonazoid and hepatobiliary phase of gadoxetic acid-enhanced MRI.
    Yang WY; Park HS; Kim YJ; Yu MH; Jung SI; Jeon HJ
    J Clin Ultrasound; 2017 Nov; 45(9):542-550. PubMed ID: 28547764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment.
    Rimola J; Davenport MS; Liu PS; Brown T; Marrero JA; McKenna BJ; Hussain HK
    Abdom Radiol (NY); 2019 Feb; 44(2):549-558. PubMed ID: 30218239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading.
    Sugimoto K; Moriyasu F; Saito K; Taira J; Saguchi T; Yoshimura N; Oshiro H; Imai Y; Shiraishi J
    J Ultrasound Med; 2012 Apr; 31(4):529-38. PubMed ID: 22441909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
    Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
    Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography.
    Nishigori S; Numata K; Irie K; Fukuda H; Chuma M; Maeda S
    J Med Ultrason (2001); 2018 Jul; 45(3):405-415. PubMed ID: 29362966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid.
    Besa C; Lewis S; Pandharipande PV; Chhatwal J; Kamath A; Cooper N; Knight-Greenfield A; Babb JS; Boffetta P; Padron N; Sirlin CB; Taouli B
    Abdom Radiol (NY); 2017 Jan; 42(1):179-190. PubMed ID: 27448609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.